Sign In
Buy BIO
$304.83
-1.30 (-0.425%)
At Close: Jun 03, 2026
BIO-key Showcases Next-Gen Identity & Biometric Authentication Solutions at Premier Tech and Cybersecurity Events: GITEX 2025 (Dubai) & 19ENISE (Spain).
Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025
07:57am, Tuesday, 07'th Oct 2025
Presentation to highlight advancements in Hoth's clinical pipeline, includingHT-001 for cancer-therapy-induced rash and HT-KIT, a novel oncology programtargeting KIT-driven tumors NEW YORK , Oct. 7, 2
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 8
Biorad Medisys announces its entry into the US market with the launch of its new subsidiary Medtimo Inc.
05:19pm, Thursday, 04'th Sep 2025
PUNE, India, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Biorad Medisys, an Indian medical device manufacturer with a global footprint, has announced its entry into the US market with the launch of its subsidi
Bio-Rad Laboratories, Inc. (BIO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)
05:07pm, Thursday, 04'th Sep 2025
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 12:45 PM EDT Company Participants Roop Lakkaraju - Executive VP & CFO Norman Schwartz - Chai
Is it Apt to Hold Bio-Rad Stock in Your Portfolio Now?
11:20am, Monday, 01'st Sep 2025
BIO's strong ddPCR growth and solid diagnostics demand support its stock despite market pressures and stiff competition.
Bio-Rad's Management to Participate in Upcoming Investor Conferences
09:00am, Monday, 25'th Aug 2025
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that members of the com
BKYI: BIO-key Q2'25 Revenue Rose 49% Driven by Increases Across All Three Segments; Launches “BIO-key CyberDefense Initiative.” Investor Call 10am ET today
Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause
07:30am, Thursday, 07'th Aug 2025
The U.S. Government plans to cut the annual budget allocated to the NIH by 40% in 2026. This decision could have an adverse effect on the operations of Bio-Rad. Bio-Rad projects 0.5% revenue growth fo
BIO-TECHNE DECLARES DIVIDEND
06:30am, Wednesday, 06'th Aug 2025
MINNEAPOLIS , Aug. 6, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30,
HOLMDEL, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer Identity and Access Management solutions featuring passwor
Bio-Rad (BIO) Q2 EPS Jumps 51%
08:25pm, Friday, 01'st Aug 2025
Bio-Rad (BIO) Q2 EPS Jumps 51%
Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings
11:30am, Friday, 01'st Aug 2025
Bio-Rad Laboratories, Inc. BIO reported better-than-expected second-quarter financial results on Thursday.
Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025
09:00am, Friday, 01'st Aug 2025
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced today that the company's mana
Bio-Rad Laboratories, Inc. (BIO) Q2 2025 Earnings Call Transcript
09:55pm, Thursday, 31'st Jul 2025
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q2 2025 Earnings Conference Call July 31, 2025 5:00 PM ET Company Participants Jonathan P. DiVincenzo - President & COO Norman D.
